USD 92.1
(-0.04%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 38.3 Million USD | 9.12% |
2022 | 35.1 Million USD | 15.08% |
2021 | 30.5 Million USD | 8.93% |
2020 | 28 Million USD | 61.96% |
2019 | 17.28 Million USD | 59.13% |
2018 | 10.86 Million USD | 134.9% |
2017 | -31.12 Million USD | 0.0% |
2016 | - USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 100.0% |
2013 | -23 Thousand USD | 99.84% |
2012 | -14.08 Million USD | 0.0% |
2011 | - USD | 0.0% |
2010 | - USD | 0.0% |
2009 | - USD | 0.0% |
2008 | - USD | 0.0% |
2007 | - USD | 0.0% |
2006 | - USD | 0.0% |
2005 | - USD | 0.0% |
2004 | - USD | 0.0% |
2003 | - USD | 0.0% |
2002 | - USD | 0.0% |
2001 | - USD | 0.0% |
2000 | - USD | 0.0% |
1999 | - USD | 0.0% |
1998 | - USD | 0.0% |
1997 | - USD | 0.0% |
1996 | - USD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q1 | 37.2 Million USD | -2.87% |
2024 Q2 | 42.5 Million USD | 14.25% |
2024 Q3 | 45.8 Million USD | 7.76% |
2023 Q3 | 28.8 Million USD | -9.15% |
2023 Q1 | 33.4 Million USD | -4.84% |
2023 Q4 | 38.3 Million USD | 32.99% |
2023 Q2 | 31.7 Million USD | -5.09% |
2023 FY | 38.3 Million USD | 9.12% |
2022 Q2 | 29.3 Million USD | 1.03% |
2022 Q4 | 35.1 Million USD | -5.14% |
2022 Q1 | 29 Million USD | -4.92% |
2022 FY | 35.1 Million USD | 15.08% |
2022 Q3 | 37 Million USD | 26.28% |
2021 FY | 30.5 Million USD | 8.93% |
2021 Q1 | 30.1 Million USD | 7.5% |
2021 Q2 | 28.3 Million USD | -5.98% |
2021 Q3 | 25.5 Million USD | -9.89% |
2021 Q4 | 30.5 Million USD | 19.61% |
2020 Q4 | 28 Million USD | 35.92% |
2020 FY | 28 Million USD | 61.96% |
2020 Q3 | 20.6 Million USD | -6.36% |
2020 Q2 | 22 Million USD | 3.77% |
2020 Q1 | 21.2 Million USD | 22.63% |
2019 Q1 | 13.01 Million USD | 19.75% |
2019 Q2 | 12.01 Million USD | -7.62% |
2019 Q3 | 10.79 Million USD | -10.15% |
2019 Q4 | 17.28 Million USD | 60.1% |
2019 FY | 17.28 Million USD | 59.13% |
2018 Q4 | 10.86 Million USD | 79.45% |
2018 Q1 | - USD | 100.0% |
2018 Q2 | - USD | 0.0% |
2018 Q3 | 6.05 Million USD | 0.0% |
2018 FY | 10.86 Million USD | 134.9% |
2017 Q1 | - USD | 0.0% |
2017 Q4 | -31.12 Million USD | -12962.4% |
2017 Q3 | 242 Thousand USD | 89.06% |
2017 Q2 | 128 Thousand USD | 0.0% |
2017 FY | -31.12 Million USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2016 Q4 | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 FY | - USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2015 Q2 | - USD | 100.0% |
2015 FY | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 Q1 | -30.03 Million USD | 0.0% |
2014 Q3 | - USD | 100.0% |
2014 Q2 | -2.91 Million USD | -55.85% |
2014 FY | - USD | 100.0% |
2014 Q1 | -1.87 Million USD | -8043.48% |
2014 Q4 | - USD | 0.0% |
2013 Q4 | -23 Thousand USD | 0.0% |
2013 FY | -23 Thousand USD | 99.84% |
2013 Q3 | - USD | 100.0% |
2013 Q1 | - USD | 100.0% |
2013 Q2 | -38 Thousand USD | 0.0% |
2012 Q1 | - USD | 0.0% |
2012 Q2 | - USD | 0.0% |
2012 Q3 | - USD | 0.0% |
2012 Q4 | -14.08 Million USD | 0.0% |
2012 FY | -14.08 Million USD | 0.0% |
2011 FY | - USD | 0.0% |
2011 Q4 | - USD | 0.0% |
2011 Q3 | - USD | 0.0% |
2011 Q2 | - USD | 0.0% |
2011 Q1 | - USD | 0.0% |
2010 Q1 | - USD | 0.0% |
2010 FY | - USD | 0.0% |
2010 Q4 | - USD | 100.0% |
2010 Q3 | -124.97 Million USD | 4.88% |
2010 Q2 | -131.38 Million USD | 0.0% |
2009 Q4 | - USD | 0.0% |
2009 Q2 | - USD | 0.0% |
2009 FY | - USD | 0.0% |
2009 Q1 | - USD | 0.0% |
2009 Q3 | - USD | 0.0% |
2008 Q3 | - USD | 0.0% |
2008 FY | - USD | 0.0% |
2008 Q1 | - USD | 0.0% |
2008 Q2 | - USD | 0.0% |
2008 Q4 | - USD | 0.0% |
2007 Q4 | - USD | 0.0% |
2007 FY | - USD | 0.0% |
2007 Q3 | - USD | 0.0% |
2007 Q2 | - USD | 0.0% |
2007 Q1 | - USD | 0.0% |
2006 Q2 | - USD | 0.0% |
2006 FY | - USD | 0.0% |
2006 Q4 | - USD | 0.0% |
2006 Q1 | - USD | 0.0% |
2006 Q3 | - USD | 0.0% |
2005 Q3 | - USD | 0.0% |
2005 FY | - USD | 0.0% |
2005 Q1 | - USD | 0.0% |
2005 Q2 | - USD | 0.0% |
2005 Q4 | - USD | 0.0% |
2004 Q1 | - USD | 0.0% |
2004 Q3 | - USD | 0.0% |
2004 Q2 | - USD | 0.0% |
2004 Q4 | - USD | 0.0% |
2004 FY | - USD | 0.0% |
2003 FY | - USD | 0.0% |
2003 Q3 | - USD | 0.0% |
2003 Q2 | - USD | 0.0% |
2003 Q1 | - USD | 0.0% |
2003 Q4 | - USD | 0.0% |
2002 FY | - USD | 0.0% |
2002 Q3 | - USD | 0.0% |
2002 Q4 | - USD | 0.0% |
2002 Q2 | - USD | 0.0% |
2002 Q1 | - USD | 0.0% |
2001 Q4 | - USD | 0.0% |
2001 FY | - USD | 0.0% |
2001 Q1 | - USD | 0.0% |
2001 Q2 | - USD | 0.0% |
2001 Q3 | - USD | 0.0% |
2000 FY | - USD | 0.0% |
2000 Q1 | - USD | 0.0% |
2000 Q2 | - USD | 0.0% |
2000 Q3 | - USD | 0.0% |
2000 Q4 | - USD | 0.0% |
1999 Q1 | - USD | 0.0% |
1999 Q2 | - USD | 0.0% |
1999 Q3 | - USD | 0.0% |
1999 Q4 | - USD | 0.0% |
1999 FY | - USD | 0.0% |
1998 Q2 | - USD | 0.0% |
1998 Q4 | - USD | 0.0% |
1998 Q1 | - USD | 0.0% |
1998 FY | - USD | 0.0% |
1998 Q3 | - USD | 0.0% |
1997 Q2 | - USD | 0.0% |
1997 Q4 | - USD | 0.0% |
1997 Q1 | - USD | 0.0% |
1997 FY | - USD | 0.0% |
1997 Q3 | - USD | 0.0% |
1996 Q4 | - USD | 0.0% |
1996 Q2 | - USD | 0.0% |
1996 Q1 | - USD | 0.0% |
1996 FY | - USD | 0.0% |
1996 Q3 | - USD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
uniQure N.V. | 12.02 Million USD | -218.53% |
Agios Pharmaceuticals, Inc. | 19.07 Million USD | -100.776% |
Amicus Therapeutics, Inc. | 59.69 Million USD | 35.842% |
Atara Biotherapeutics, Inc. | 9.7 Million USD | -294.601% |
bluebird bio, Inc. | 22.91 Million USD | -67.11% |
Cara Therapeutics, Inc. | 2.82 Million USD | -1257.675% |
Imunon, Inc. | - USD | -Infinity% |
Editas Medicine, Inc. | - USD | -Infinity% |
IQVIA Holdings Inc. | - USD | -Infinity% |
Mettler-Toledo International Inc. | 385.86 Million USD | 90.074% |
Myriad Genetics, Inc. | 20.1 Million USD | -90.547% |
Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 50.522% |
Verastem, Inc. | - USD | -Infinity% |
Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.54% |
Waters Corporation | 516.23 Million USD | 92.581% |
Thermo Fisher Scientific Inc. | 5.08 Billion USD | 99.247% |
Biogen Inc. | 2.52 Billion USD | 98.485% |
Nektar Therapeutics | 16.1 Million USD | -137.873% |
Perrigo Company plc | 1.14 Billion USD | 96.643% |
Dynavax Technologies Corporation | 53.29 Million USD | 28.129% |
Illumina, Inc. | 587 Million USD | 93.475% |
Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Iovance Biotherapeutics, Inc. | 10.37 Million USD | -269.263% |
Heron Therapeutics, Inc. | 42.11 Million USD | 9.048% |
Unity Biotechnology, Inc. | - USD | -Infinity% |
BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 96.541% |
Sangamo Therapeutics, Inc. | - USD | -Infinity% |
Evolus, Inc. | 10.99 Million USD | -248.245% |
Adicet Bio, Inc. | - USD | -Infinity% |
Aclaris Therapeutics, Inc. | - USD | -Infinity% |
Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 98.516% |
Esperion Therapeutics, Inc. | 65.62 Million USD | 41.636% |
FibroGen, Inc. | 41.56 Million USD | 7.855% |
Agilent Technologies, Inc. | 1.03 Billion USD | 96.285% |
OPKO Health, Inc. | 65.69 Million USD | 41.702% |
Homology Medicines, Inc. | - USD | -Infinity% |
Geron Corporation | - USD | -Infinity% |
Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 57.037% |
Exelixis, Inc. | 17.32 Million USD | -121.093% |
Viking Therapeutics, Inc. | - USD | -Infinity% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
Intellia Therapeutics, Inc. | - USD | -Infinity% |
Zoetis Inc. | 2.56 Billion USD | 98.506% |
Axsome Therapeutics, Inc. | 15.13 Million USD | -153.056% |
Abeona Therapeutics Inc. | -2.44 Million USD | 1667.103% |
Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 94.816% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -34.741% |
Sarepta Therapeutics, Inc. | 322.85 Million USD | 88.137% |
Corcept Therapeutics Incorporated | 7.73 Million USD | -395.472% |
Halozyme Therapeutics, Inc. | 127.6 Million USD | 69.985% |
Blueprint Medicines Corporation | 21.22 Million USD | -80.465% |
Insmed Incorporated | 83.24 Million USD | 53.993% |
TG Therapeutics, Inc. | 39.82 Million USD | 3.824% |
Incyte Corporation | 62.97 Million USD | 39.179% |
Emergent BioSolutions Inc. | 328.9 Million USD | 88.355% |